Navigation Links
Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
Date:12/18/2009

SAN DIEGO and TOKYO, Dec. 18 /PRNewswire/ -- Ambit Biosciences Corporation and Astellas Pharma Inc. today announced that they have entered into a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. This partnership includes AC220, Ambit's lead clinical-stage investigational drug that entered into a Phase 2 clinical trial earlier this month in relapsed/refractory acute myeloid leukemia (AML), and other undisclosed FLT3 kinase inhibitors. AC220 is a novel, orally available, potent and highly selective small molecule that was specifically designed as a second generation FMS-like tyrosine kinase-3 (FLT3) inhibitor using Ambit's proprietary drug discovery engine, KINOMEscan(TM).

The companies will collaborate to develop AC220 for AML and other indications. The parties will also collaborate on a research and development program for a series of novel FLT3 inhibitors for a variety of oncology and non-oncology indications. The companies will share equally in the responsibilities and expenses for the development of AC220 and any additional products in the U.S. and Europe, while Astellas will have sole responsibility to fund development in all other territories. Under the terms of the agreement, Ambit will receive an up-front cash payment of $40 million and will be eligible to receive pre-commercialization payments of up to $350 million.

Astellas will have sole responsibility for funding and implementing the commercialization of all products, and Ambit will be entitled to post-approval milestone payments upon the achievement of certain sales thresholds, as well as tiered double-digit royalties on net sales. In the U.S., Ambit will also have the option to co-promote AC220 and other products under a profit sharing arrangement where Astellas and Ambit share equally in profits and losses generated from U.S. sales.

"We are pleased
'/>"/>

SOURCE Ambit Biosciences Corporation; Astellas Pharma Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference
2. Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting
3. Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium
4. CeloNova BioSciences CEO Urges More Heart, More Passion, More Honesty, and All Urgency in Developing Medical Devices
5. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
6. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
7. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
8. Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results
9. Cell Biosciences Completes Acquisition of Alpha Innotech
10. Neurocrine Biosciences Reports Third Quarter 2009 Results
11. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... plc (NYSE: MNK ) announced today that ... program. The open-ended authorization permits the company to repurchase ... "Funding additional initiatives and seeking attractive ... to pursue a range of focused growth strategies," said ...
(Date:1/23/2015)... 23, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... the development and sale of patented biopharmaceutical medicine, modernized ... ingredients (API) today announced the business and development progress ... 1. Following the September 2014 JCM application (No. ...
(Date:1/22/2015)... 22, 2015  Uroplasty, Inc. (NASDAQ: UPI ), a ... proprietary products to treat voiding dysfunctions, today reported financial ... 2014.  Global revenue for the Company,s Urgent ... a new quarterly revenue record, as compared to $3.9 ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
(Date:1/22/2015)... Four years since the release of their debut recording Love is ... Avasa & Matthew Love – the duo are pleased to announce ... White Swan Records on February 24, 2015. , THE ROAD offers ... to all of us to walk out of the mire of ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and ... relationship in an effort to further promote visibility and adoption ... has long made AMA journals available via its subscription services, ... JAMA Network. , Long known as both a ...
(Date:1/22/2015)... JJsHouse.com is a famous dress online store for wedding ... its latest collection of wedding dresses , and launches a ... the wedding dress on your big day; the wedding gown ... bride wants to find the most suitable wedding dress. Now, ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Lower-Auto-Insurance.com has released a ... kit in a car for reducing the costs of an ... will also be able to get lower prices for their vehicle ... an important role in determining policy costs. Because of this, ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 State Forestry ... data management system with support from GEOSYSTEMS, a dedicated ... new solution will leverage Hexagon Geospatial’s ERDAS APOLLO ... data as well as point clouds and documents. This ...
Breaking Medicine News(10 mins):Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... , THURSDAY, March 15 (HealthDay News) -- People who ... more likely to have vascular disease in the brain that ... study included 511 women with an average age of 69 ... 10 years. The women,s eyes were tested about four years ...
... confirmed that there is a clear relationship between androgenetic ... a benign enlargement of the prostate that appears in ... dihydrotestosterone. This condition appears in 50% of men over ... frequency. In the light of the study published ...
... 2012) As the supply of life-saving antibiotics ... systems and policymakers to step up efforts to ... antibiotics through antimicrobial stewardship initiatives. A ... Epidemiology of America (SHEA), Infectious Diseases Society of ...
... in the Journal of Clinical Oncology found ... with acute lymphoblastic leukemia (ALL), the most common childhood ... the years 1990-1994, to 90.4 percent for those diagnosed ... due to using existing drugs better, not because of ...
... -- A catheter procedure that closes a hole in patients, ... recurrent strokes, according to a new study published in the ... Medicine . In the CLOSURE I trial, clinical ... alone to prevent new strokes or transient ischemic attacks (TIAs) ...
... which top 10 to 15 per cent of their body weight ... online in the Archives of Disease in Childhood . ... researchers. They assessed the back health of 1403 pupils between ... one province in North Western Spain. The teens were weighed ...
Cached Medicine News:Health News:Eyes a Window Into Brain Health: Study 2Health News:A study confirms the correlation between premature alopecia and prostate conditions 2Health News:Leading infectious diseases experts call for increased focus on protecting antibiotics 2Health News:Largest ever study of childhood ALL shows improving survival 2Health News:Study finds expensive procedure no more effective than medical therapy to prevent strokes 2Health News:Study finds expensive procedure no more effective than medical therapy to prevent strokes 3Health News:Heavy rucksacks storing up back problems for many school-kids 2
Streptavidin MicroBeads are used for the indirect magnetic labeling and separation of cells, subcellular material, or bacteria labeled with a biotinylated primary antibody or ligand....
Malaria antibody EIA 480 test kit...
... For the detection P.falciparum ... and pan specific pLDH, for differentiation ... other malarial species viz P.vivax ... P. malariae and for the ...
Malaria Pf. Assay Range...
Medicine Products: